Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

@article{Jones2005LiveAR,
  title={Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses},
  author={Steven J M Jones and Heinz Feldmann and Ute Ströher and Joan B. Geisbert and Lisa Fernando and Allen Grolla and Hans Dieter Klenk and Nancy J. Sullivan and Viktor E. Volchkov and Elizabeth A. Fritz and Kathleen M Daddario and Lisa E Hensley and Peter B. Jahrling and Thomas W. Geisbert},
  journal={Nature Medicine},
  year={2005},
  volume={11},
  pages={786-790}
}
Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here, we developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective… 
Evaluation of the Protective Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against Marburg Hemorrhagic Fever in Nonhuman Primate Models
TLDR
The data suggests that these replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors are safe and highly efficacious in a relevant animal model.
Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates
TLDR
These data are the first to show 100% protective efficacy against any high dose filov virus challenge beyond 8 weeks after final vaccination, demonstrating the durability of VSV-based filovirus vaccines.
Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species
TLDR
This report provides the first demonstration of vaccine-induced protective immunity against challenge with a heterologous EBOV species, and shows that Ebola vaccines capable of eliciting potent cellular immunity may provide the best strategy for eliciting cross-protection against newly emerging heterologicous E BOV species.
Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections
TLDR
Vaccination of nonhuman primates demonstrated 100% protection against infection by two species of Ebola virus and three Marburg virus subtypes, each administered at 1,000 times the lethal dose.
An Ebola whole-virus vaccine is protective in nonhuman primates
TLDR
It is demonstrated that a whole Ebola virus (EBOV) vaccine based on a replication-defective, peroxide-treated whole-virus vaccine candidate for Ebola shows promise in macaques, and represents a safe, efficacious, whole-E BOV vaccine candidates in that it presents all viral proteins and the viral RNA to the host immune system, which might contribute to protective immune responses.
A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques
TLDR
Results demonstrate that a novel bivalent, spherical Ebola virus-like particle (VLP) vaccine elicits strong humoral and cellular immune responses against pathogenic Ebola viruses and support further evaluation of this approach as a potential addition to Ebola vaccine development efforts.
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
TLDR
On the basis of safety and efficacy, eVLP-vaccinated monkeys survived challenge without clinical or laboratory signs of EBOV infection, whereas the control animal died of infection.
Protection of Nonhuman Primates against Two Species of Ebola Virus Infection with a Single Complex Adenovirus Vector
TLDR
EBO7 vaccine provided protection against both Ebola viruses by either route of infection, and protection against SEBOV given as an aerosol challenge, which has not previously been shown, could be achieved with a boosting vaccination.
An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
TLDR
It is demonstrated that guinea pigs immunized with Ad5-MakGP developed robust humoral responses and were protected against exposure to guinea pig-adapted EBOV and conferred 100% protection when animals were challenged 4 weeks after immunization.
Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection
TLDR
A new vaccine platform, expressing two antigens resulting in assembly of VLPs in the native conformation in vaccinated hosts, can be used as a potent vaccine against MARV.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
TLDR
The development of accelerated vaccination against Ebola virus in non-human primates provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses.
Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
TLDR
The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.
Development of a preventive vaccine for Ebola virus infection in primates
TLDR
A combination of DNA immunization and boosting with adenoviral vectors that encode viral proteins generated cellular and humoral immunity in cynomolgus macaques demonstrates that it is possible to develop a preventive vaccine against Ebola virus infection in primates.
Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.
TLDR
An RNA replicon, based upon Venezuelan equine encephalitis (VEE) virus, was used as a vaccine vector; the VEE structural genes were replaced by genes for MBGV GP, nucleoprotein (NP), VP40, VP35, VP30, or VP24.
An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants
TLDR
An AIDS vaccine based on attenuated VSV vectors expressing env and gag genes and tested it in rhesus monkeys, finding protection from AIDS was highly significant.
Towards a vaccine against Ebola virus
TLDR
A brief historic look at attempts to develop an efficacious vaccine is taken, an overview of current vaccine candidates and strategies that have the greatest potential for commercial development are provided.
Successful Vaccine-Induced Seroconversion by Single-Dose Immunization in the Presence of Measles Virus-Specific Maternal Antibodies
TLDR
The induction of neutralizing antibodies increased with increasing virus dose, and all doses gave good protection from subsequent challenge with MV, which is key to the induction of a neutralizing antibody in the presence of a maternal antibody.
Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors
TLDR
Two new VSV vectors expressing HA are generated which are completely attenuated for pathogenesis in the mouse model and provide complete protection from lethal influenza virus challenge after intranasal administration.
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.
TLDR
Effective treatment of Ebola infections may require a combination of drugs that inhibit viral replication in monocyte/macrophage-like cells while reversing the pathologic effects (e.g., coagulopathy) consequent to this replication.
Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing an Influenza Virus Hemagglutinin Provides Complete Protection from Influenza Virus Challenge
TLDR
VSV-HA is an effective intranasal vaccine vector that raises high levels of neutralizing antibody to influenza virus and completely protects mice from bronchial pneumonia caused by challenge with a lethal dose of influenza A virus.
...
1
2
3
4
...